Long-acting antibody medicines for asthma, COPD and eczema · Basel, Switzerland
Priced Nov 12, 2026 · range was $16–$18 · latest SEC filing Nov 16, 2026.
Pinch-zoom for details.
Windward Bio is a clinical-stage biotech developing ultra-long-acting antibody medicines for asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
Its candidates, WIN378 and WIN027, are designed to stay in the body longer than current treatments so patients need fewer doses. It has no approved products.
Fiscal year
1st half
Fiscal year
1st half
| $ | Jul 5–Dec 31, 2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (1.19M) | (51.8M) | n/m | (23.3M) | (44.7M) | −91.9% |
| Net result | (1.19M) | (48.3M) | n/m | (22.8M) | (42.6M) | −87.4% |
| $ | Jul 5–Dec 31, 2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (1.19M) | (51.8M) | n/m |
| Net result | (1.19M) | (48.3M) | n/m |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (23.3M) | (44.7M) | −91.9% |
| Net result | (22.8M) | (42.6M) | −87.4% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
In plain English, from the filing's risk factors.
The filing doesn't set out its strategy in a list we could read.
Source: WINDWARD BIO GROUP AG's Form F-1/A, filed with the SEC on Nov 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back